LONDON--(BUSINESS WIRE)--Technavio has announced their latest drug pipeline analysis report on cataract therapeutics. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat cataract.
This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Cataract: Market overview
Cataract can be defined as a type of disease that arises due to the clouding of the eye’s natural lens, which lies behind iris and pupil. Cataract can start at any age, and sometimes, it may be present from birth. It begins when the protein in the eye forms clumps and prevents the lens from sending clear images to the retina. Companies are focusing on developing molecules with heat shock proteins, also known as alpha crystalline, which prevents misfolded proteins from aggregating in the lens of the eye. For instance, Plex Pharmaceuticals developed a novel compound, which is an alpha crystalline activator that helps in maintaining proper refractive index in the lens. This delay prevents the formation of cataracts, the major cause of blindness in the world.
Cataract therapeutics: Segmentation analysis
This pipeline analysis report segments the cataract therapeutics market based on therapies employed (monotherapy), RoA (opthalmic and topical), therapeutic modality (small molecule, monoclonal antibody and protein), targets (glucocorticoid receptor, alpha-crystallin, beta-L crystallin, calpain, G8 receptor, nerve growth factor receptor, and protein aggregation), MoA (glucocorticoid receptor agonist, alpha-crystallin activator, beta-L crystallin inhibitor, calpain inhibitor, G8 receptor inhibitor, nerve growth factor receptor agonist, and protein aggregation inhibitor), geographical segmentation (US and Italy) and recruitment status (completed and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Based on therapeutic modality, close to 67% of the molecules that are being investigated for the treatment of cataract are small molecule.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- Therapeutic modality
- Geographical coverage
- Recruitment status
- Type of players
- Company overview
Discontinued or Dormant Molecules
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at email@example.com.